EMA Puts Temporary Restrictions on Tofacitinib Due to PE Risk EMA Puts Temporary Restrictions on Tofacitinib Due to PE Risk

The EMA ' s safety committee advises physicians not to prescribe the 10-mg twice-daily dose of tofacitinib to patients who are at high risk for pulmonary embolism, pending results of an ongoing safety review.News Alerts
Source: Medscape Internal Medicine Headlines - Category: Internal Medicine Tags: Rheumatology News Alert Source Type: news